EPB163	Real-world HIV renal outcomes with TDF-to-TAF switch	E-poster	Regimen simplification and switch studies
EPB164	Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care	E-poster	Regimen simplification and switch studies
EPB165	Changes in inflammatory biomarkers and baseline variables after switching to dolutegravir/lamivudine (DTG/3TC) in 2 randomized clinical trials of virologically suppressed adults: 48-week pooled analysis	E-poster	Regimen simplification and switch studies
EPB166	Rapid tenofovir-lamivudine-dolutegravir transition in Papua New Guinea: a virtual approach to antiretroviral prescriber refresher trainings during a global pandemic	E-poster	Regimen simplification and switch studies
EPB167	Intermittent doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains viral suppression in real life in controlled HIV-infected patients	E-poster	Regimen simplification and switch studies
EPB168	Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study	E-poster	Regimen simplification and switch studies
EPB169	Efficacy and safety of switching to Dolutegravir/Lamivudine by baseline regimen in virologically suppressed adults: 48-week pooled analysis	E-poster	Regimen simplification and switch studies
EPB170	Changes innonalcoholicfatty liverdiseasespectrum and metabolic markers in people with HIV after switching to a raltegravir-based regimen	E-poster	Regimen simplification and switch studies
EPB171	Efficacy of Tenofovir alafenamide versus tenofovir disoproxil fumarate among HIV positive Zambian adults switched from NNRTI to dolutegravir-containing ART: results from the VISEND clinical trial	E-poster	Regimen simplification and switch studies
EPLBB04	Randomised study of switch toDTG/RPV in subjects with HIV RNA <50c/ml and archived K103N over 48 weeks	E-poster	Regimen simplification and switch studies